Skip to main content
Menu
Enter your keywords
Why Us?
Our Services
Health Economics
Decision-Analytic Models
Database Studies
Delphi Panels
Literature Reviews and Meta-analyses
Analysis of Heterogeneity of Treatment Effects
Retrospective Chart Reviews
Economic Qualitative Inquiry, Policy, and Access
Patient-Centered Outcomes Assessment
Measurement Strategies
Instrument Development
Psychometric Evaluation
Utility Assessment
Market Research
Regulatory Guidance and Support
Market Access and Outcomes Strategy
Market Access and Evidence Generation Strategies
Systematic and Other Literature Reviews
Global Value Dossiers and Other Value Communication Materials
PIE and Post-Approval AMCP Dossiers
Health Preference Assessment
Discrete Choice Experiments and Conjoint Analysis
Benefit-Risk Preferences
Willingness-to-Pay
Multi-Criteria Decision Analysis
Pharmacoepidemiology and Risk Management
Regulatory RWE Consulting
Database and Registry Research
RWE Studies Using Primary Data Collection
Literature Reviews
Collaborative Regulatory RWE Research
Surveys and Observational Studies
Biostatistics
Clinical Trials
Observational Studies
Real-World Evidence
Benefit-Risk Assessment
HTA and Reimbursement Submissions
Research Team
Therapeutic Experience
Autoimmune Diseases
Cardiovascular
CNS/Neurology
Dermatology
Diabetes & Endocrine Disorders
Gastroenterology
Hematology
Infectious Disease
Medical Technologies
Men's Health
Oncology
Ophthalmology
Pain
Psychiatry
Rare Diseases
Regenerative Therapy
Respiratory
Rheumatology
Vaccines
Women's Health
Publications
Careers
Benefits
Career Development
Employee Stories
Locations
Meaningful Work
Our Culture
Contact
Updates and Events
Updates
Events
For the Media
Resources
Webinars
Knowledgebase Infographics
Case Studies
Videos
Breadcrumb
Home
Publications
Extra Scrutiny For Industry Funded Trials
Rothman KJ
, Evans S.
Extra scrutiny for industry funded trials
. BMJ. 2005 Jan 1;331(7529):1350-1.
Abstract not available at this time.
Share on:
